Atopic Dermatitis: Global Drug Forecast and Market Analysis to 2027
Summary
Global sales in the atopic dermatitis market are expected to grow to $18.3B by 2027, at a Compound Annual Growth Rate (CAGR) of 11.1% from 2017-2027. It is estimated that sales of drugs in the atopic dermatitis market were approximately $6.4B in 2017 in the 7MM (United States, France, Germany, Italy, Spain, United Kingdom and Japan).
The US was the largest market, with approximately $5.1B in drug sales, which represented 80% of the total atopic dermatitis market. The 5EU market contributed $1.1B in sales and Japan contributed sales of $202M in 2017. It is forecasted that the US to grow to $13.6B, followed by 5EU (France, Germany, Italy, Spain, United Kingdom) and Japan.
Atopic dermatitis is a widespread chronic inflammatory skin condition that can affect patients of all ages and is the result of a complex interplay of environmental, immunological, genetic, and pharmacologic factors. The atopic dermatitis market has historically remained stagnant and the pipeline for drugs in late-stage development was lacking, but recent developments have reignited interest in the treatment of the disease, especially as the estimated drug-treated population may grow to 24,000,000 people over the next decade.
The atopic dermatitis pipeline has traditionally been focused on topical therapies, with Pfizer’s Eucrisa being the latest to be approved in December 2016. Until the launch of Regeneron/Sanofi’s Dupixent in March 2017, severe atopic dermatitis patients had to be prescribed systemic immunomodulators, which are associated with a slew of side effects. However, the arrival of Dupixent, a first-in-class monoclonal antibody (mAb), addressed the unmet needs of these severe patients. The pipeline mostly comprises systemic therapies targeting the moderate-to-severe population.
The report Atopic Dermatitis: Global Drug Forecast and Market Analysis to 2027, provides key metrics for atopic dermatitis (Epidemiology, Market Size, Product Pipeline, Key Events, Competitive Analysis) in the seven major pharmaceutical markets (7MM) covered in this report-the US, 5EU (France, Germany, Italy, Spain, and the UK), and Japan-during the forecast period from 2017-2027.
Key Questions Answered
- The projected entry of pipeline agents such as the Interleukin inhibitors and the JAK inhibitors during the forecast period is expected to spur intense growth within the atopic dermatitis market. How do products compete against each other? Which of these drugs will have the highest peak sales, and why?
- Key Opinion Leaders (KOLs) interviewed by GlobalData have indicated that there are considerably high unmet needs within the atopic dermatitis indication. What are the main unmet needs in this market? How can the pharmaceutical industry address these needs? To what degree will the therapies under development fulfill these unmet needs?
- The atopic dermatitis market is likely to remain a dynamic, growing space throughout the forecast period and beyond. Which companies are set to be major players in atopic dermatitis during the forecast period?
- Overview of atopic dermatitis including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Annualized atopic dermatitis therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2017 and forecast for ten years to 2027.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the atopic dermatitis therapeutics market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global atopic dermatitis therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global atopic dermatitis therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global atopic dermatitis therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global atopic dermatitis therapeutics market from 2017-2027.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- 1 Table of Contents
- 1.1 List of Tables
- 1.2 List of Figures
- 2 Atopic Dermatitis: Executive Summary
- 2.1 Atopic Dermatitis Market to Experience Strong Growth from 20172027
- 2.2 Late-Stage Pipeline Product Launches Will Result in New Players Establishing Themselves
- 2.3 Persistent Unmet Needs Will Be Addressed Over the Forecast Period
- 2.4 Interleukin Inhibitors and Janus Kinase Inhibitors Dominate the Atopic Dermatitis Pipeline
- 2.5 What Do Physicians Think?
- 3 Introduction
- 3.1 Catalyst
- 3.2 Related Reports
- 3.3 Upcoming Related Reports
- 4 Disease Overview
- 4.1 Etiology and Pathophysiology
- 4.1.1 Etiology
- 4.1.2 Pathophysiology
- 4.2 Classification or Staging Systems
- 5 Epidemiology
- 5.1 Disease Background
- 5.2 Risk Factors and Comorbidities
- 5.3 Global and Historical Trends
- 5.4 Forecast Methodology
- 5.4.1 Sources
- 5.4.2 Forecast Assumptions and Methods - Population
- 5.4.3 Forecast Assumptions and Methods - One-Year Total and Diagnosed Prevalent Cases of Atopic Dermatitis
- 5.4.4 Forecast Assumptions and Methods - One-Year Total Prevalent Cases of Atopic Dermatitis by Severity
- 5.4.5 Forecast Assumptions and Methods - One-Year Diagnosed Prevalent Cases of Atopic Dermatitis by Severity
- 5.5 Epidemiological Forecast for Atopic Dermatitis (20172027)
- 5.5.1 One-Year Total Prevalent Cases of Atopic Dermatitis
- 5.5.2 Age-Specific One-Year Total Prevalent Cases of Atopic Dermatitis
- 5.5.3 Sex-Specific One-Year Total Prevalent Cases of Atopic Dermatitis
- 5.5.4 One-Year Total Prevalent Cases of Atopic Dermatitis by Severity
- 5.5.5 One-Year Diagnosed Prevalent Cases of Atopic Dermatitis
- 5.5.6 Age-Specific One-Year Diagnosed Prevalent Cases of Atopic Dermatitis
- 5.5.7 Sex-Specific One-Year Diagnosed Prevalent Cases of Atopic Dermatitis
- 5.5.8 One-Year Diagnosed Prevalent Cases of Atopic Dermatitis by Severity
- 5.6 Discussion
- 5.6.1 Epidemiological Forecast Insight
- 5.6.2 Limitations of the Analysis
- 5.6.3 Strengths of the Analysis
- 6 Disease Management
- 6.1 Diagnosis and Treatment Overview
- 6.2 US
- 6.3 5EU
- 6.4 Japan
- 7 Competitive Assessment
- 7.1 Overview
- 8 Unmet Needs and Opportunity Assessment
- 8.1 Overview
- 8.2 Topical Treatments Without Side Effects
- 8.3 A Drug that Effectively Controls Patients’ Pruritus
- 8.4 Addressing Heterogeneity in the Pathophysiology of Atopic Dermatitis
- 8.5 Improved Patient Compliance and Education
- 9 Pipeline Assessment
- 9.1 Overview
- 9.2 Promising Drugs in Clinical Development
- 10 Current and Future Players
- 10.1 Overview
- 10.2 Trends in Corporate Strategy
- 10.3 Company Profiles
- 10.3.1 LEO Pharma
- 10.3.2 Pfizer
- 10.3.3 Regeneron
- 10.3.4 AbbVie
- 10.3.5 Dermira
- 10.3.6 Eli Lilly
- 10.3.7 Galderma
- 10.3.8 Incyte
- 10.4 Other Players
- 11 Market Outlook
- 11.1 Global Markets
- 11.1.1 Forecast
- 11.1.2 Drivers and Barriers - Global Issues
- 11.2 US
- 11.2.1 Forecast
- 11.2.2 Key Events
- 11.2.3 Drivers and Barriers
- 11.3 5EU
- 11.3.1 Forecast
- 11.3.2 Key Events
- 11.3.3 Drivers and Barriers
- 11.4 Japan
- 11.4.1 Forecast
- 11.4.2 Key Events
- 11.4.3 Drivers and Barriers
- 12 Appendix
- 12.1 Bibliography
- 12.2 Abbreviations
- 12.3 Methodology
- 12.3.1 Forecasting Methodology
- 12.3.2 Diagnosed Patients
- 12.3.3 Percent Drug-Treated Patients
- 12.3.4 Drugs Included in Each Therapeutic Class
- 12.3.5 Launch and Patent Expiry Dates
- 12.3.6 General Pricing Assumptions
- 12.3.7 Individual Drug Assumptions
- 12.3.8 Generic Erosion
- 12.3.9 Pricing of Pipeline Agents
- 12.4 Primary Research - Key Opinion Leaders and Payers Interviewed for This Report
- 12.4.1 Key Opinion Leaders
- 12.4.2 Payers
- 12.5 Primary Research - Prescriber Survey
- 12.6 About the Authors
- 12.6.1 Analyst
- 12.6.2 Reviewer
- 12.6.3 Therapy Area Director
- 12.6.4 Epidemiologist
- 12.6.5 Managing Epidemiologists
- 12.6.6 Global Director of Therapy Analysis and Epidemiology
- 12.6.7 Global Head and EVP of Healthcare Operations and Strategy
- 12.7 About GlobalData
- 12.8 Contact Us
- 12.9 Disclaimer
- 1.1 List of Tables
- Table 1: Atopic Dermatitis: Key Metrics in the 7MM
- Table 2: Risk Factors and Comorbid Conditions Associated with Atopic Dermatitis
- Table 3: Treatment Guidelines for Atopic Dermatitis
- Table 4: Country Profile - US
- Table 5: Country Profile - 5EU
- Table 6: Country Profile - Japan
- Table 7: Leading Treatments for Atopic Dermatitis, 2017
- Table 8: Comparison of Therapeutic Classes in the Development for Atopic Dermatitis, 2017-2027
- Table 9: LEO Pharma’s Atopic Dermatitis Portfolio Assessment, 2018
- Table 10: Pfizer’s Atopic Dermatitis Portfolio Assessment, 2018
- Table 11: Regeneron’s Atopic Dermatitis Portfolio Assessment, 2018
- Table 12: AbbVie’s Atopic Dermatitis Portfolio Assessment, 2018
- Table 13: Dermira’s Atopic Dermatitis Portfolio Assessment, 2018
- Table 14: Eli Lilly’s Atopic Dermatitis Portfolio Assessment, 2018
- Table 15: Galderma’s Atopic Dermatitis Portfolio Assessment, 2018
- Table 16: Incyte’s Disease Portfolio Assessment, 2018
- Table 17: Atopic Dermatitis Market - Global Drivers and Barriers, 2017-2027
- Table 18: Key Events Impacting Sales for Atopic Dermatitis in the US, 2017-2027
- Table 19: Atopic Dermatitis Market - Drivers and Barriers in the US, 2017-2027
- Table 20: Key Events Impacting Sales for Atopic Dermatitis in the 5EU, 2017-2027
- Table 21: Atopic Dermatitis Market - Drivers and Barriers in the 5EU, 2017-2027
- Table 22: Key Events Impacting Sales for Atopic Dermatitis in Japan, 2017-2027
- Table 23: Atopic Dermatitis Market - Global Drivers and Barriers in Japan, 2017-2027
- Table 24: Key Projected Launch Dates for Atopic Dermatitis
- Table 25: Key Historical and Projected Patent Expiry Dates for Atopic Dermatitis
- Table 26: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
- 1.2 List of Figures
- Figure 1: Global Sales Forecast by Country for Atopic Dermatitis in 2017 and 2027
- Figure 2: Analysis of the Company Portfolio Gap in Atopic Dermatitis During the Forecast Period
- Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of Atopic Dermatitis During the Forecast Period
- Figure 4: Major Drug Targets for Atopic Dermatitis Treatment
- Figure 5: 7MM, Age-Standardized One-Year Total Prevalence of Atopic Dermatitis (%), Both Sexes, All Ages, 2017
- Figure 6: 7MM, Sources Used and Not Used to Forecast the One-Year Total and Diagnosed Prevalent Cases of Atopic Dermatitis
- Figure 7: 7MM, Sources Used to Forecast the One-Year Total Prevalence by Severity of Atopic Dermatitis
- Figure 8: 7MM, Sources Used to Forecast the One-Year Diagnosed Prevalent Cases by Severity of Atopic Dermatitis
- Figure 9: 7MM, One-Year Total Prevalent Cases of Atopic Dermatitis, Both Sexes, All Ages, N, 2017
- Figure 10: 7MM, Age-Specific One-Year Total Prevalent Cases of Atopic Dermatitis, Both Sexes, All Ages, N, 2017
- Figure 11: 7MM, Sex-Specific One-Year Total Prevalent Cases of Atopic Dermatitis, All Ages, N, 2017
- Figure 12: 7MM, One-Year Total Prevalent Cases of Atopic Dermatitis by Severity, Both Sexes, All Ages, N, 2017
- Figure 13: 7MM, One-Year Diagnosed Prevalent Cases of Atopic Dermatitis, Both Sexes, All Ages, N, 2017
- Figure 14: 7MM, Age-Specific One-Year Diagnosed Prevalent Cases of Atopic Dermatitis, Both Sexes, All Ages, N, 2017
- Figure 15: 7MM, Sex-Specific One-Year Diagnosed Prevalent Cases of Atopic Dermatitis, All Ages, N, 2017
- Figure 16: 7MM, One-Year Diagnosed Prevalent Cases by Severity of Atopic Dermatitis, Both Sexes, All Ages, N, 2017
- Figure 17: Flowchart of the Diagnosis and Management of Atopic Dermatitis
- Figure 18: Unmet Needs and Opportunities in Atopic Dermatitis
- Figure 19: Overview of the Development Pipeline in Atopic Dermatitis
- Figure 20: Key Phase II/III Trials for the Promising Pipeline Agents that GlobalData Expects to Be Licensed for Atopic Dermatitis in the 7MM During the Forecast Period
- Figure 21: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of Atopic Dermatitis During the Forecast Period
- Figure 22: Analysis of the Company Portfolio Gap in Atopic Dermatitis During the Forecast Period
- Figure 23: Global (7MM) Sales Forecast for Atopic Dermatitis by Country in 2017 and 2027
- Figure 24: Sales Forecast for Atopic Dermatitis by Class in the US in 2017 and 2027
- Figure 25: Sales Forecast for Atopic Dermatitis in the 5EU by Class in 2017 and 2027
- Figure 26: Sales Forecast for Atopic Dermatitis by Class in Japan in 2017 and 2027
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook